DaShenLin Pharmaceutical Group Co

DaShenLin Pharmaceutical Group Co AAQS

The The AAQS of DaShenLin Pharmaceutical Group Co (603233.SS) as of Oct 30, 2026 is 10. In the previous year, The AAQS was 10.00 — a change of 0.00% (lower).

AAQS

10

YoY

0.00%

Last updated:

DaShenLin Pharmaceutical Group Co has a current AAQS of 10.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock DaShenLin Pharmaceutical Group Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The DaShenLin Pharmaceutical Group Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
10.00 CNY
Jan 1, 2019
10.00 CNY
Jan 1, 2020
10.00 CNY
Jan 1, 2021
10.00 CNY
Jan 1, 2022
10.00 CNY
Jan 1, 2023
10.00 CNY
Jan 1, 2024
10.00 CNY
Jan 1, 2025
10.00 CNY
The DaShenLin Pharmaceutical Group Co AAQS history
YEARAAQSYoY
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DaShenLin Pharmaceutical Group Co Stock analysis

What does DaShenLin Pharmaceutical Group Co do? DaShenLin Pharmaceutical Group Co Ltd generates revenue through the retail and wholesale of pharmaceutical products, including Chinese and Western medicine, ginseng nourishing herbs, Chinese medicine pieces, health products, and medical apparatus. The company operates primarily within the domestic market, serving customers who purchase these healthcare commodities directly or through its retail channels. Its business model relies on direct sales and retailing as key revenue streams, targeting consumers and businesses seeking pharmaceutical and health-related products. The firm's product portfolio encompasses a wide range of healthcare items, from traditional Chinese medicine to modern medical devices, all sold under its own brand within China's domestic market. With a focus on both direct sales and retail distribution, DaShenLin Pharmaceutical Group Co Ltd caters to a diverse customer base that includes individual consumers and healthcare institutions requiring medical supplies and health products. DaShenLin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaShenLin Pharmaceutical Group Co stock

The AAQS of DaShenLin Pharmaceutical Group Co is 10 in 2025.

On Eulerpool you can find the complete historical development of The AAQS DaShenLin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — DaShenLin Pharmaceutical Group Co

All Key Metrics — DaShenLin Pharmaceutical Group Co